Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,

Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market

Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe

Merck and Orion announce option providing Merck global exclusive rights to Opevesostat

An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer

Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets

CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia

Insect biotech as India's next deeptech opportunity: Ankit Alok Bagaria, Co-founder and CEO, Loopworm

We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River

Bayer introduces chemo-free treatment option for advanced prostate cancer in India

Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets